Johnson & Johnson's (JNJ) Management Presents at Raymond James 43rd Institutional Investors Conference (Transcript)

Mar. 08, 2022 5:10 PM ETJohnson & Johnson (JNJ)1 Comment
SA Transcripts profile picture
SA Transcripts

Johnson & Johnson (NYSE:JNJ) Raymond James 43rd Institutional Investors Conference March 8, 2022 1:05 PM ET

Company Participants

Joe Wolk – Chief Financial Officer

Jess Moore – Vice President, Investor Relations

Conference Call Participants

Jayson Bedford – Raymond James

Jayson Bedford

All right. Let’s get started here. My name is Jayson Bedford. I’m the Medical Device Analyst here. Again, welcome to the second day of the 43rd Annual Raymond James Institutional Investors Conference and Happy International Women’s Day. So with us, we have the senior management team of Johnson & Johnson. The largest healthcare company in the world. We have the company’s CFO, Joe Wolk. We have the company’s VP Investor Relations, Jess Moore. And we also have Lisa Romano upfront here.

So with that, I’m going to give Joe a couple minutes just to talk about why he’s excited about J&J’s positioning and what excites him going forward. And then we’ll jump into to Q&A.

Joe Wolk

Great. Thanks, Jayson. Certainly it’s a pleasure to be here with all of you here in the room in person. I want to complement and congratulate Raymond James. This is the first healthcare conference that I’ve been in person that probably two years and I imagine many in the room can say the same thing. Listen Jayson, I think there’s a lot of reasons to be excited about Johnson & Johnson’s business moving forward into 2022, but also well beyond if I think about our pharmaceutical unit, which quite frankly we think is best-in-class.

We’ve got a great inline portfolio today that’s going to deliver growth above market. We believe for the 11th consecutive year. And then we’ve got a pipeline right behind it that will really serve the second half of this decade extremely well overcoming any loss of exclusivity concerns that folks

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.